Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2120997 | 0.85 | ALDH1A1 (0.42) | ALDH1A1HPGDLMNAMEN1KMT2A | |
| SCHEMBL28125752 | 0.84 | ALDH1A1 (0.56) | ALDH1A1HPGDLMNAMEN1KMT2A | |
| SCHEMBL8358409 | 0.78 | ALDH1A1 (0.51) | ALDH1A1HPGDLMNAMEN1KMT2A | |
| SCHEMBL1747096 | 0.77 | ALDH1A1 (0.50) | ALDH1A1HPGDLMNAMEN1KMT2A | |
| SCHEMBL24715944 | 0.77 | ALDH1A1 (0.50) | ALDH1A1HPGDLMNAMEN1KMT2A | |
| SCHEMBL31553097 | 0.77 | HTR2A (0.35) | — | |
| SCHEMBL23218543 | 0.74 | KMT2A (0.42) | ALDH1A1HPGDKMT2AKDM4EHSD17B10 | |
| SCHEMBL16844564 | 0.74 | HTR2A (0.35) | ALDH1A1 | |
| SCHEMBL2122119 | 0.73 | IMPDH2 (0.54) | ALDH1A1HPGDLMNAMEN1KMT2A | |
| SCHEMBL2992833 | 0.73 | ALDH1A1 (0.50) | ALDH1A1HPGDLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3093017-A1 | PHARMACEUTICAL COMPOSITION COMPRISING (S)-(3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL FOR USE IN TREATING MAMMALIAN CONDITIONS | ALLERGAN, INC. (US) | 2016-11-16 | — | — | EP | claimed |
| EP-2734200-A1 | ALPHA-2 ADRENERGIC MODULATORS FOR TREATING VISUAL DISORDERS MEDIATED BY CENTRAL VISUAL PROJECTIONS FROM THE EYE | Allergan, Inc. (US) | 2014-05-28 | — | — | EP | claimed |
| WO-2013016073-A1 | ALPHA-2 ADRENERGIC MODULATORS FOR TREATING VISUAL DISORDERS MEDIATED BY CENTRAL VISUAL PROJECTIONS FROM THE EYE | ALLERGAN, INC. (US) | 2013-01-31 | — | — | WO | claimed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| EP-3659600-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING RETINAL DISEASES | ALLERGAN, INC. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-10603331-B2 | Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-31 | — | — | US | disclosed |
| US-20190142852-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-05-16 | — | — | US | disclosed |
| US-10064879-B2 | Method for treating depression and/or depression status with substituted quinoxaline compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-09-04 | — | — | US | disclosed |
| US-20170224713-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| EP-3093017-A1 | PHARMACEUTICAL COMPOSITION COMPRISING (S)-(3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL FOR USE IN TREATING MAMMALIAN CONDITIONS | ALLERGAN, INC. (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20120101124-A1 | 1,2,4-OXADIAZOL DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS SPHINGOSINE 1-PHOSPHATE 1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2443111-A1 | 1,2,4-OXADIAZOL DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS SPHINGOSINE 1-PHOSPHATE 1 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-04-25 | — | — | EP | disclosed |
| WO-2012037499-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL | ALLERGAN, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012036253-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-22 | — | — | WO | disclosed |
| US-20110152246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2010145203-A1 | 1,2,4-OXADIAZOL DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS SPHINGOSINE 1-PHOSPHATE 1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010145203-A1 | 1,2,4-OXADIAZOL DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS SPHINGOSINE 1-PHOSPHATE 1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010093930-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | ALLERGAN, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | ALDH1A1 1739/4885HPGD 1039/4885LMNA 258/4885 |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | ALDH1A1 2027/4885HPGD 318/4885LMNA 437/4885 |
| US-20170224713-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | HCRTR1, NPSR1, NTSR1 | ALDH1A1 2931/4885HPGD 789/4885LMNA 1124/4885 |
| US-20190142852-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | HCRTR1, NPSR1, NTSR1 | ALDH1A1 2931/4885HPGD 789/4885LMNA 1124/4885 |
| US-20120101124-A1 | 1,2,4-OXADIAZOL DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS SPHINGOSINE 1-PHOSPHATE 1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | ALDH1A1 1772/4885HPGD 1322/4885LMNA 2987/4885 |
| US-20110152246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, IRF3 | ALDH1A1 1679/4885HPGD 3113/4885LMNA 2659/4885 |
| US-10603331-B2 | Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | MC2R, PNMT, SLC6A2 | ALDH1A1 1841/4885HPGD 495/4885LMNA 730/4885 |
| US-10064879-B2 | Method for treating depression and/or depression status with substituted quinoxaline compounds | KYNU, CRH, CHRM1 | ALDH1A1 1905/4885HPGD 634/4885LMNA 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.